Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1159713 | 0.89 | KMT2A (0.63) | HDAC1HDAC6CA12CA1CA2 | |
| SCHEMBL15319511 | 0.88 | CA12 (0.56) | HDAC1HDAC6CA12CA1CA2 | |
| SCHEMBL3996984 | 0.88 | SMN1; SMN2 (0.59) | HDAC1HDAC6CA12CA1CA2 | |
| SCHEMBL13400097 | 0.88 | HDAC1 (0.50) | HDAC1HDAC6CA12CA1CA2 | |
| SCHEMBL7265002 | 0.86 | CA12 (0.73) | CA12CA1CA2CA9MAPT | |
| SCHEMBL16416372 | 0.83 | CA12 (0.51) | HDAC1HDAC6CA12CA1CA2 | |
| SCHEMBL3351763 | 0.82 | KMT2A (0.60) | MAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL3204160 | 0.81 | HRH3 (0.71) | HDAC1HDAC6MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL3247417 | 0.81 | MEN1 (0.49) | HDAC1HDAC6CA12CA1CA2 | |
| SCHEMBL10310251 | 0.81 | KMT2A (0.57) | HDAC1HDAC6CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4716685-A1 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2026-04-01 | — | — | EP | disclosed |
| US-20260070906-A1 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2026-03-12 | — | — | US | disclosed |
| WO-2024240726-A1 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2024-11-28 | — | — | WO | disclosed |
| US-20100331312-A1 | MODULATORS OF THE HISTAMINE H3 RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| EP-2265587-A1 | MODULATORS OF THE HISTAMINE H3 RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009105206-A1 | MODULATORS OF THE HISTAMINE H3 RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070906-A1 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | TLR1, TLR6, TLR8 | HDAC1 648/4885HDAC6 964/4885CA12 2926/4885 |
| US-20100331312-A1 | MODULATORS OF THE HISTAMINE H3 RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HRH3, HRH4, HRH1 | HDAC1 258/4885HDAC6 572/4885CA12 3484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.